

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)



ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
APPLICANT Sommadosi, <i>et al.</i>	CONFIRMATION NO. 8101
FILING DATE June 27, 2003	ART UNIT 1623

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A01	4,605,659	8/12/86	Verheyden et al.	
A02	5,034,394	7/23/91	Daluge	
A03	5,122,517	6/16/92	Vince et al.	
A04	5,977,325	11/2/99	McCarthy et al.	
A05	6,156,501	12/05/00	McGall et al.	
A06	6,596,700	7/22/03	Sommadosi et al.	
A07	6,833,361	12/21/04	Hong et al.	
A08	6,927,291	8/9/05	Jin et al.	
A09	6,946,115	9/20/05	Erion et al.	
A10	6,949,522	9/27/05	Otto et al.	
A11	7,094,770	8/22/06	Watanabe et al.	
A12	7,144,868	12/5/06	Roberts et al.	
A13	7,151,089	12/19/06	Roberts et al.	
A14	7,157,434	1/2/07	Keicher et al.	
A15	7,202,224	4/10/07	Eldrup et al.	
A16	2004/0229839	11/18/04	Babu et al.	
A17	2004/0259934	12/23/04	Olsen et al.	
A18	2004/0266996	12/30/04	Rabi et al.	
A19	2005/0038240	02/17/05	Connolly et al.	
A20	2005/0137141	06/23/05	Hilfinger et al.	
A21	2005/0215511	09/29/05	Roberts et al.	
A22	2006/0040890	02/23/06	Martin et al.	
A23	2006/0111311	05/25/06	Keicher et al.	
A24	2006/0194835	08/31/06	Dugourd et al.	
A25	2006/0241064	10/26/06	Roberts et al.	
A26	2007/0015905	1/18/07	LaColla et al.	
A27	2007/0060503	3/15/07	Gosselin et al.	
A28	2007/0060504	3/15/07	Gosselin et al.	

LAI-2899573v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
	APPLICANT Sommadosi, <i>et al.</i>	CONFIRMATION NO. 8101
	FILING DATE June 27, 2003	ART UNIT 1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A29	11/005,443	12/6/04	Gosselin et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	CA 2252144	4/16/00	Xia, et al.		
	B02	DD 140254	2/20/80	Barwolff, et al.		
	B03	DE 42 24 737	2/03/94	Schott		
	B04	DE 102005012681	09/21/06	Weber, Lutz		
	B05	EP 0 352 248	1/24/90	Medivir AM		
	B06	EP 0 526 655	2/10/93	Japan Tobacco Inc.		
	B07	EP 0 553 358	8/04/93	Japan Tobacco Inc.		
	B08	EP 0 587 364	3/16/94	Britton, et al.		
	B09	EP 0 742 287	11/13/96	McGall, et al.		
	B10	GB 1,542,442	3/21/79	Schering AG		
	B11	JP 2091022	3/30/90	Univ. of Minnesota		
	B12	JP 61212592	9/20/86	Tokyo Tanabe Co. Ltd.		
	B13	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.		
	B14	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.		
	B15	JP 06135988	5/17/94	Toagosei Chemical Ind., Ltd.		
	B16	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho		
	B17	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.		
	B18	WO 99/023104	5/14/99	Dept. of Health and Human Services		
	B19	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B20	WO 00/025799	5/11/00	Gosselin, et al.		
	B21	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B22	WO 01/091737	12/06/01	Sommadosi, et al.		

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
	APPLICANT Sommadosi, <i>et al.</i>	CONFIRMATION NO. 8101
	FILING DATE June 27, 2003	ART UNIT 1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B23	WO 02/070533	9/12/02	Pharmasset		
	B24	WO 03/068244	8/21/03	Merck & Co. Isis Pharmaceuticals		
	B25	WO 03/039523	5/15/03	Exiqon A/S		
	B26	WO 03/051899	6/26/03	Ribapharm		
	B27	WO 03/063771	8/7/03	Pharmasset		
	B28	WO 03/068162	8/21/03	Pharmasset		
	B29	WO 03/068164	8/21/03	Pharmasset		
	B30	WO 03/099840	12/04/03	Isis Pharmaceuticals		
	B31	WO 03/100017	12/04/03	Eldrup, et al.		
	B32	WO 03/106577	12/24/03	Weikard, et al.		
	B33	WO 04/002422	1/8/04	Idenix Pharma.; Univ. D.S. Cagliari		
	B34	WO 04/041203	05/21/04	Xenoport, Inc., USA		
	B35	WO 04/043977	5/27/04	Prakush, et al.		
	B36	WO 04/043978	5/27/04	Baker, et al.		
	B37	WO 04/044132	5/27/04	Baker, et al.		
	B38	WO 04/046331	06/03/04	Idenix Cayman		
	B39	WO 04/052899	06/24/04	Idenix Cayman Limited		
	B40	WO 04/058792	07/15/04	Idenix Cayman Limited		
	B41	WO 04/065398	8/5/04	Ribapharm, Inc.		
	B42	WO 04/072090	8/26/04	Merck & Co., Inc.		
	B43	WO 04/080466	9/23/04	Ribapharm, Inc.		
	B44	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B45	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B46	WO 04/106356	12/9/04	Syddansk Univeritet		
	B47	WO 05/003147	01/13/05	Pharmasset, Ltd.		
	B48	WO 05/012327	2/10/05	University College Cardiff Consultants Limited		
	B49	WO 05/020884	03/10/05	CENT NAT RECH SCI.		
	B50	WO 05/020885	03/10/05	Isis Pharmaceuticals, Inc., USA		

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
APPLICANT Sommadosi, <i>et al.</i>	CONFIRMATION NO. 8101
FILING DATE June 27, 2003	ART UNIT 1623

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B51	WO 05/021568	3/10/05	Biota, Inc.		
	B52	WO 05/030258	4/07/05	Dihedron Corp.		
	B53	WO 05/042556	05/12/05	Genelabs Technologies, Inc., USA		
	B54	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B55	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
	B56	WO 06/012078	2/02/06	Merck & Co., Inc.		
	B57	WO 06/016930	02/16/06	Intermune, Inc.		
	B58	WO 06/037028	04/06/06	CENT NAT RECH SCI		
	B59	WO 06/037227	04/13/06	Migenix Inc., Can.		
	B60	WO 06/063717	6/22/06	Universitaet Karlsruhe		
	B61	WO 06/065335	06/22/06	Merck & Co. Inc., USA		
	B62	WO 06/097323	09/21/06	Weber, Lutz		
	B63	WO 06/100087	09/28/06	Novartis A.-G.		
	B64	WO 06/121820	11/16/06	Valeant Research & Development		
	B65	WO 06/130532	12/07/06	Novartis AG, Switz.		
	B66	WO 07/011777	01/25/07	Novartis A.-G., Switz.		
	B67	WO 07/025304	01/03/07	University of Oxford; Idenix Pharmaceuticals; et al.		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	ALT et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," <i>Hepatology</i> , 22 :707-717 (1995).	
	C02	ALT, et al., "Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation." <i>Arch. Virol.</i> 142 :589-599 (1997).	
	C03	BEIGELMAN et al., "Functionally complete analogs of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. <i>Biorganicheskaya Khimiya</i> 12(10) :1359-1365 (1986).	
	C04	BERENGUER et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," <i>Proceedings of the Association of American Physicians</i> , 110(2) :98-112 (1998).	
	C05	BHOPALE et al., "Emerging drugs for chronic hepatitis C," <i>Hepatology Research</i> 32(3) :146-153 (2005).	

LAI-2899573v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
	APPLICANT	CONFIRMATION NO.
	Sommadossi, <i>et al.</i>	8101
	FILING DATE	ART UNIT
	June 27, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C06	BILLICH et al., "Nucleoside phosphotransferase from malt sprouts. I. Isolation, characterization and specificity of the enzyme" Biol. Chem. Hoppe-Seyler, 367 :267-278 (1986).	
	C07	BIO et al., "Practical synthesis of a potent hepatitis C virus RNA replication inhibitor." Journal of Organic Chemistry 69 (19):6257-6266 (2004).	
	C08	BLOCH et al., "The role of the 5'-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase," J. Med. Chem., 10 (5):908-12 (1967).	
	C09	BROWN and McFARLIN et al., "The reaction of Lithium aluminum hydride with alcohols. Lithium tri- <i>t</i> -butoxy-aluminumhydride as a new selective reducing agent", J. Am. Chem. Soc. 80 :5372-5376 (1958)	
	C10	BRYANT et al., "Antiviral L-nucleosides specific for hepatitis B virus infection," Antimicrobial Agents and Chemotherapy, 45 (1):229-235 (2001).	
	C11	CAPPELLACCI et al., "Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists." Journal of Medicinal Chemistry 48 (5):1550-1562 (2005).	
	C12	CARROLL, "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets 6 (1):17-29 (2006).	
	C13	CAVELIER et al., "Studies of selective boc removal in the presence of silyl ethers," Tetrahedron Letters 37 : 5131-5134 (1996).	
	C14	CHAND et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series), 7(Chemistry of Nucleic Acid Components): 329-332 (2005).	
	C15	CHIARAMONTE et al., "Inhibition of CMP-sialic acid transport into Golgi vesicles by nucleoside monophates." Biochemistry 40 (47):14260-14267 (2001).	
	C16	CLARK et al., "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication." Journal of Medicinal Chemistry 48 (17):5504-5508 (2005).	
	C17	COELMONT et al., "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy 50 (10):3444-3446 (2006).	
	C18	COOKE, "Improving the treatment of hepatitis C infection in the UK," Expert Opinion on Pharmacotherapy, (2007) Vol. 8, No. 2, pp. 183-191.	
	C19	CORNBERG et al., "Present and future therapy for hepatitis C virus," Expert Review of Anti-Infective Therapy 4 (5):781-793 (2006).	
	C20	CRETTON-SCOTT et al., "Pharmacokinetics of B-L-2'-deoxyctidine prodrugs in monkeys," Antiviral Res., 50 :A44 (2001).	
	C21	CZERNECKI et al., "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," J. Org. Chem., 57 :7325-7328 (1992).	
	C22	DALPIAZ et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." European Journal of Pharmacology 448 (2-3):123-131 (2002).	
	C23	DAVIS, "New therapies: Oral inhibitors and immune modulators," Clinics in Liver Disease 10 (4): 867-880 (2006).	
	C24	DAVISSON et al., "Synthesis of nucleotide 5'-diphosphates from 5'-O-tosyl nucleosides," J. Org. Chem. 52 (9):1794-1801 (1987).	
	C25	DING et al., "Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters 15 (3):709-713 (2005)	
	C26	DING et al., "Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters 15 (3):725-727 (2005).	

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
	APPLICANT Sommadossi, <i>et al.</i>	CONFIRMATION NO. 8101
	FILING DATE June 27, 2003	ART UNIT 1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C27	DUTARTRE et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," <i>Antimicrobial Agents and Chemotherapy</i> 50(12) :4161-4169 (2006).	
	C28	ELDRUP et al., "Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication," <i>Journal of Medicinal Chemistry</i> 47(21) :5284-5297 (2004).	
	C29	ELDRUP et al., "Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase," <i>Journal of Medicinal Chemistry</i> 47(9) : 2283-2295 (2004).	
	C30	FAIVRE-BUET et al., "Synthesis of 1'-deoxyspicofuanosyl-dexonucleosides as potential anti-HIV agents," <i>Nucleosides & Nucleotides</i> , 11(7) :1411-1424 (1992).	
	C31	FOX et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," <i>J. Am. Chem. Soc.</i> 81 : 178-187 (1959).	
	C32	FRANCHETTI et al., "Antitumor activity of C-methyl-β-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors," <i>Journal of Medicinal Chemistry</i> 48(15) :4983-4989 (2005).	
	C33	FUJIMORI et al., "A convenient and stereoselective synthesis of 2'-deoxy-β-L-nucleosides," <i>Nucleosides & Nucleotides</i> , 11(2-4) : 341-349 (1992); only CAPLUS abstract supplied.	
	C34	FURUKAWA et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," <i>Chem. Pharm. Bull.</i> , 16(6) :1076-1080 (1968).	
	C35	GALDERISI et al., "Antisense oligonucleotides as therapeutic agents," <i>Journal of Cellular Physiology</i> , 181(2) :251-257 (1999).	
	C36	GALLO et al., "2'-C-methyluridine phosphoramidite: A new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group," <i>Tetrahedron</i> 57 : 5707-5713 (2001).	
	C37	GRETCH, "Use and interpretation of HCV diagnostic tests in the clinical setting," <i>Clinics in Live Disease</i> , 1(3) :547-557 (1997).	
	C38	GIRARDET et al., "Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides," <i>Journal of Medicinal Chemistry</i> 43(20) :3704-3713 (2000).	
	C39	GROUILLER et al., "Novel-p-toluenesulfonylation and thionocarbonylation of unprotected thymine nucleosides," <i>Synlett</i> , 1993: 221-222 (1993).	
	C40	GROUILLER et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent," <i>J. Pharm. Belg.</i> , 47(4) :381-383 (1992).	
	C41	HARAGUCHI et al., "Preparation and reactions of 2'- and 3'- vinyl bromides of uracil nucleosides: versatile synthons for anti-HIV agents," <i>Tetrahedron Letters</i> 32(28) :3391-3394 (1991).	
	C42	HARAGUCHI et al., "Stereoselective synthesis of 1'-C-branched uracil nucleosides from uridine," <i>Nucleotides & Nucleosides</i> 14(3-5) :417-420 (1995).	
	C43	HARRY-O'KURU et al., "2'-C-alkylribonucleosides: Design, synthesis and conformation," <i>Nucleosides & Nucleotides</i> 16 :1457-1460 (1997).	
	C44	HATTORI et al., "Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and -uracil," <i>J. Med. Chem.</i> 41(15) : 2892-2902 (1998).	
	C45	HAYAKAWA et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: Synthesis of uracil nucleosides branched at the 2'- and 3'-positions," <i>Chemical & Pharmaceutical Bulletin</i> 35(6) :2605-2608 (1987).	
	C46	HOARD et al., "Conversion of mono- and oligodeoxyribonucleotides to 5'-triphosphates," <i>J. Am Chem. Soc.</i> , 87(8) :1785-1788 (1965).	

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
	APPLICANT	CONFIRMATION NO.
	Sommadossi, <i>et al.</i>	8101
	FILING DATE	ART UNIT
	June 27, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C47	HOLY, "Nucleic acid components and their analogs. CLIII. Preparation of 2'-deoxy-L-ribonucleosides for the pyrimidine series," Collect. Czech. Chem. Commun., 37(12) :4072-4087 (1972).	
	C48	IGLESIAS et al., "Complete and regioselective deacetylation of peracetylated uridines using a lipase." Biotechnology Letters 22 : 361-365 (2000).	
	C49	IIMORI et al., "2'-C-, 3'-C-, and 5'-C-methylsangivamycins: Conformational lock with the methyl group." Tetrahedron Letters 32(49) :7273-7276 (1991).	
	C50	IIMORI et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series, Nineteenth Symposium on Nucleic Acids Chemistry, 27 :169-170 (1992).	
	C51	IINO T., et al., "Nucleosides and nucleotides 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines," Nucleosides & Nucleotides, 15(1-3) : 169-181 (1996).	
	C52	IKEGASHIRA et al., "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry 49(24) :6950-6953 (2006).	
	C53	IMAI et al., "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides." J. Org. Chem. 34(6) :1547-1550 (1969).	
	C54	ITOH et al., "Divergent and stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position," J. Org. Chem. 60(3) : 656-662 (1995).	
	C55	KAKEFUDA et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: Synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron 49(38) : 8513-8528 (1993).	
	C56	KAMAIKE et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, [6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nucleosides and Nucleotides, 15(1-3) :749-769 (1996).	
	C57	KANEKO et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20 :1050-1053 (1972).	
	C58	KEMPE et al., "Selective 2'-benzoylation at the cis 2', 3'-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures," Nucleic Acids Res. 10(21) :6695-6714 (1982).	
	C59	KERR et al., "N-4-(Dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications." J. Pharm. Sci. 83(4) : 582-586 (1994).	
	C60	KLUMPP et al., "The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture," Journal of Biological Chemistry 281(7) :3793-3799 (2006).	
	C61	KIM et al., "A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein," Molecular Pharmaceutics 1(2) :117-127 (2004).	
	C62	KOTRA, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosides." J. Med. Chem. 1997, 40 , 3635-3644.	
	C63	KUHN, R., et al., "Über eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C64	LAI et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependent RNA polymerase," J. Virol. 73(12) :10129-10136 (1999).	
	C65	LANDOWSKI, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics 316(2) : 572-580 (2006).	
	C66	LE POGAM et al., "In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance." Virology 351 : 349-359 (2006).	

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11874-026-999	APPLICATION NO. 10/607,909
	APPLICANT Sommadossi, <i>et al.</i>	CONFIRMATION NO. 8101
	FILING DATE June 27, 2003	ART UNIT 1623

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C67	LE POGAM et al., "Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus." <i>Journal of Virology</i> 80(12) : 6146-6154 (2006).	
	C68	LIN et al., "Synthesis of several pyrimidine L-nucleoside analogues as potential antiviral agents," <i>Tetrahedron Letters</i> 51(4) : 1055-1068 (1995).	
	C69	LOPEZ-HERRERA et al., "A new synthesis of 2-C methyl-D-ribo-1, 4-lactone and the C-(C-13 fragment of methynolide," <i>J. Carbohydrate Chemistry</i> 13(5) : 767-775 (1994).	
	C70	LOPEZ APARICIO et al., "Synthesis of saccharinic acid derivatives," <i>Carbohydrate Res.</i> 129 :99 (1984).	
	C71	MAGA et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," <i>Biochem. J.</i> 294(Part2) : 381-385 (1993).	
	C72	MANSSOUR et al., "Editorial," <i>Anti-Infective Agents in Medicinal Chemistry</i> , (2007) Vol. 6, No. 1, pp. 1.	
	C73	MARKLAND et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," <i>Antimicrobial Agents and Chemotherapy</i> 44 (4) : 859-866 (2000).	
	C74	MARTIN et al., "Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)." <i>J. Med. Chem.</i> 33(8) : 2137-2145 (1990).	
	C75	MATSUDA et al., "Nucleosides and nucleotides. 104. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides." <i>Nucleosides & Nucleotides</i> 11(2/4) : 197-226 (1992).	
	C76	The Merck Index, 12th edition, 1996, Page 275	
	C77	MILES et al., "Circular dichroism of nucleoside derivatives. IX. Vicinal effects on the circular dichroism of pyrimidine nucleosides." <i>Journal of the American Chemical Society</i> 92(13) :3872-3881 (1970).	
	C78	MOORE et al., "Synthesis of nucleotide analogues that potently and selectively inhibit human DNA primase." <i>Biochemistry</i> 41(47) : 14066-14075 (2002).	
	C79	MOISEYEV et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." <i>FEBS Letters</i> 404(2,3) : 169-172 (1997)	
	C80	NISHIGUCHI et al., "Methods to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy," <i>Hepatology</i> 33(1) : 241-247 (2001).	
	C81	NISHIMURA et al., "Studies on synthetic nucleosides. Trimethylsilyl derivatives of pyrimidine and purines," <i>Chemical & Pharmaceutical Bulletin</i> 12 : 352-356 (1964).	
	C82	NOVAK & SORM, "Nucleic acid components and their analogues. CXX. 2-C-methyl-D-ribose and its derivatives," <i>Collection Czechoslov. Chem. Commun.</i> 34 :857-866 (1969).	
	C83	NOVAK, "Chiroptical properties of 2-methyl-1,4-lactones; Revised absolute configuration of 2-deoxy-2-C-methyl-erythro-D-pentono-1, 4-lactones," <i>Collection Czechoslov. Chem. Commun.</i> 39 :869-882 (1974).	
	C84	PAGLIARO et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. <i>EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI</i> ," <i>Recenti Progressi in Medicina</i> , 97(12) : 741-750 (2006).	
	C85	PIERRA et al., "Comparative studies of selected potential prodrugs of B-L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50 :A79 (2001), Abstract no. 138.	
	C86	PIERRA et al., "NM 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Nucleosides, Nucleotides and Nucleic Acids</i> 24(5-7) : 767-770 (2005).	
	C87	PIERRA et al., "Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Journal of Medicinal Chemistry</i> 49(22) : 6614-6620 (2006).	

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11874-026-999

APPLICATION NO.

10/607,909

APPLICANTSommadosi, *et al.***CONFIRMATION NO.**

8101

FILING DATE

June 27, 2003

ART UNIT

1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C88	REIST et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." <i>Journal of Organic Chemistry</i> 27 :3279-3283 (1962).	
	C89	ROBINS et al., "Purine Nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their [alpha] anomers," <i>Journal of Organic Chemistry</i> 35 (3): 636-639 (1970).	
	C90	ROQUE-AFONSO et al., "Performance of TRUGENE hepatitis C virus 5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," <i>Journal of Viral Hepatitis</i> 9 (5): 385-389 (2002).	
	C91	RONG et al., "The Synthesis and conformation of 2'- and 3'-hypermodified tricyclic nucleosides and their use in the synthesis of novel 2'- or 3'-isomeric 4(7)-substituted isoxazolidine-nucleosides," <i>Tetrahedron</i> 50 (16): 4921-4936 (1994).	
	C92	SANDHU et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." <i>Drug Metabolism and Disposition</i> 32 (11): 1254-1259 (2004)	
	C93	SAKTHIVEL et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3-deazaadenosine analogs." <i>Tetrahedron Letters</i> 46 (22): 3883-3887 (2005).	
	C94	SAKTHIVEL et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." <i>Synlett</i> 2005, 10 : 1586-1590 (2005).	
	C95	SALADINO et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," <i>J. Chem. Soc., Perkin Trans. I.</i> , 21 : 3053-3054 (1994).	
	C96	SATO, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." <i>Tetrahedron Letters</i> (1980), 21 (20), 1971-4.	
	C97	SATO et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." <i>Bulletin of the Chemical Society of Japan</i> , 56 (9): 2680-2699 (1983).	
	C98	SAVOCHKINA, et al., "Substrate Properties of C-MethylNucleoside Triphosphates in RNA Syntheses Catalyzed by E. Coli RNA - Polymerase." <i>Molecular Biology</i> , 1989, v. 23, no. 6.	
	C99	SCHEIBLER, "Ueber das Saccharin und die Saccharinsäure," <i>Chemische Berichte</i> 13 :2212-2217 (1880). In German.	
	C100	SCHIFF, "Emerging strategies for pegylated interferon combination therapy," <i>Nature Clinical Practice Gastroenterology and Hepatology</i> 4 (SUPPL. 1): S17-S21 (2007).	
	C101	SHIM, "Recent patents on nucleoside and nucleotide inhibitors for HCV," <i>Recent Patents on Anti-Infective Drug Discovery</i> 1 (3): 323-331 (2006).	
	C102	SMITH et al., "Synthesis of new 2'-β-C-methyl related tricyclic analogues as anti-HCV agents." <i>Bioorganic & Medicinal Chemistry Letters</i> 14 (13): 3517-3520 (2004).	
	C103	SONG et al., "Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevation, and hPEPT1-mediated transport," <i>Molecular Pharmaceutics</i> 2 (2): 157-167 (2005).	
	C104	SORBERA et al., "Valopicitabine: anti-hepatitis C virus drug RNA-directed RNA polymerase (NS5B) inhibitor," <i>Drugs of the Future</i> 31 (4): 320-324 (2006).	
	C105	SOWDEN, "The Saccharinic Acids," <i>Adv. Carbohydrate Chem.</i> 12 :43-46 (1957).	
	C106	SPARDARI et al., "L-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth," <i>Journal of Medicinal Chemistry</i> 35 (22): 4214-4220 (1992).	
	C107	STANDRING et al., "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," <i>Antiviral Chem. & Chemother.</i> 12 (Suppl. 1): 119-129 (2001).	
	C108	STUYVER et al., "Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture." <i>Antimicrobial Agents and Chemotherapy</i> 47 (1): 244-254 (2003).	

LAI-2899573v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-026-999	10/607,909
	APPLICANT	CONFIRMATION NO.
	Sommadossi, <i>et al.</i>	8101
	FILING DATE	ART UNIT
	June 27, 2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C109	SUNDBERG et al., Advanced Organic Chemistry, Part b, pages 232 and 236 (1990).	
	C110	TAKENUKI et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." Chemical & Pharmaceutical Bulletin 38(11) : 2947-2952 (1990).	
	C111	TANG et al., "2'-C-branched ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-β-methylcytidine and their incorporation into oligonucleotides," J. Org. Chem. 64(3) : 747-754 (1999).	
	C112	TYRSTED et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," Biochem. Biophys. Acta. 155(2) : 619-622 (1968).	
	C113	USUI et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," Chem. Pharm. Bull., 34(1) : 15-23 (1986).	
	C114	VERRI et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents," Molecular Pharmacology, 51(1) : 132-138 (1997).	
	C115	VERRI et al., "Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues," Biochem. J. 328(1) : 317-320 (1997).	
	C116	VON BUREN et al., "Branched oligodeoxynucleotides: Automated synthesis and triple helical hybridization studies." Tetrahedron 51(31) : 8491-8506 (1995).	
	C117	VON JANTA-LIPINISKI et al., "Newly synthesized L-enantiomers of 3'-fluoro-modified β-2'-deoxyribonucleoside 5'-triphosphates inhibit hepatitis B DNA polymerase but not the five cellular SNA Polymerases α, β, γ, δ and ε nor HIV-1 reverse transcriptase," J. Medicinal Chemistry 41(12) : 2040-2046 (1998).	
	C118	WAGNER et al., "Preparation and synthetic utility of some organotin derivatives of nucleosides," J. Org. Chem., 39(1) : 24-30 (1974).	
	C119	WHISTLER AND BEMILLER, "[118] 'a'-D-glucosaccharino-1,4-lactone," Methods in Carbohydrate Chemistry, 2 : 484-485 (1963).	
	C120	WOHNSLAND et al., "Viral determinants of resistance to treatment in patients with hepatitis C," Clinical Microbiology Reviews 20 (1) : 23-38 (2007).	
	C121	ZEMPLICKA et al., "Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. VIII. The preparation of 2'(3) -O-L-phenylalanyluridine, -cytidine, -adenosine, -inosine, -guanosine and 2'-deoxy-3' O-L-phenylalanyladenosine," Collection Czechoslov. Chem. Commun. 43(13) : 5239-5249 (1969).	
	C122	ZEMPLICKA et al., "Substrate specificity of ribosomal peptidyltransferase. Peptidyltransferase. Effect of modifications in the heterocyclic, carbohydrate and amino acid moiety of 2'(3)-O-L-phenyladenosine." Biochemistry 14(24) : 5239-5249 (1975)	
	C123	ZINICHENKO et al., "Substrate specificity of uridine and purine nucleoside phosphorylases of the whole cells of Escherichia coli." Nucleic Acids Research, Symposium Series No. 18., pp. 137-140 (1987).	
	C124	ZINICHENKO, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological translocation." Doklady Akad. Nauk v. 297(3), pp. 731-734.	
	C125	ZINICHENKO, et al., "Substrate specificity of uridine and purine nucleoside phosphorylases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	

LAI-2899573v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Università Degli Studi Di Cagliari.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Signed this ____ day of _____, 2007.

Università Degli Studi Di Cagliari

By: _____

Name: ADOLFO LAI

Position: PRO RETTORE



Certifico io Ufficiale Rogante Sostituto dell'Università degli Studi di Cagliari che la firma, apposta in mia presenza dal Prof. Adolfo Lai nato a Ottana il 28.07.1943, Pro Rettore dell'Università di Cagliari e della cui identità personale sono certo, è autentica

21 SET. 2007

L'Ufficiale Rogante Sostituto
Dr. Achille Filiberto Putzu

